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Abstract
Background: While methicillin-resistant Staphylococcus aureus (MRSA) originally was associated with healthcare, distinct
strains later emerged in patients with no prior hospital contact. The epidemiology of MRSA continues to evolve.
Methods: To characterize the current epidemiology of MRSA-colonized patients entering a hospital serving both rural and
urban communities, we interviewed patients with MRSA-positive admission nasal swabs between August 2009 and March
2010. We applied hospitalization risk factor, antimicrobial resistance phenotype, and multi-locus sequence genotype (MLST)
classification schemes to 94 case-patients.
Results: By MLST analysis, we identified 15 strains with two dominant clonal complexes (CCs)–CC5 (51 isolates), historically
associated with hospitals, and CC8 (27 isolates), historically of community origin. Among patients with CC5 isolates, 43%
reported no history of hospitalization within the past six months; for CC8, 67% reported the same. Classification by
hospitalization risk factor did not correlate strongly with genotypic classification. Sensitivity of isolates to ciprofloxacin,
clindamycin, or amikacin was associated with the CC8 genotype; however, among CC8 strains, 59% were resistant to
ciprofloxacin, 15% to clindamycin, and 15% to amikacin.
Conclusions: Hospitalization history was not a strong surrogate for the CC5 genotype. Conversely, patients with a history of
hospitalization were identified with the CC8 genotype. Although ciprofloxacin, clindamycin, and amikacin susceptibility
distinguished CC8 strains, the high prevalence of ciprofloxacin resistance limited its predictive value. As CC8 strains become
established in healthcare settings and CC5 strains disseminate into the community, community-associated MRSA definitions
based on case-patient hospitalization history may prove less valuable in tracking community MRSA strains.
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Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) is one of the
most commonly detected antimicrobial-resistant pathogens glob-
ally and is a major public health concern in the United States
[1,2]. Among S. aureus isolates from a U.S. network of over 300
microbiology laboratories, the number resistant to methicillin
nearly doubled between 1999 and 2006, with over 50% of S. aureus
strains from both inpatients and outpatients identified as
methicillin-resistant in 2006 [1].
The epidemiology of this pathogen, originally associated with
hospitals, is changing rapidly [3]. In the 1990s, distinct strains
emerged in patients with no prior hospital contact [4,5]. The
prevalence of such community-associated (CA-)MRSA strains has
been increasing over time [1,3,6]. In 2004, MRSA nasal
colonization was estimated at 1.5% of the U.S. population, or
approximately 4 million people [7]. Nasal colonization increases
risk for later development of MRSA infection [8].
Isolates from patients with community-associated MRSA
historically demonstrate several important differences compared
to healthcare-associated strains, including molecular differences
identified by typing methods, e.g. pulsed-field gel electrophoresis
(PFGE) [9] or multi-locus sequence typing (MLST) [10]. For
example, the USA300/CC8 strains that are most commonly
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virulence factor Panton Valentine leukocidin (PVL) cytotoxin and
are more likely to be susceptible to certain antimicrobial agents
commonly used to treat MRSA, particularly clindamycin [10–12]
and aminoglycosides [11,13]. Recently, these distinctions have
begun to blur as community strains become ‘‘domesticated’’ to
the hospital and healthcare settings [11,14–18] and hospital
strains ‘‘go feral’’ and establish in the community [19]. Despite
changes in epidemiologic patterns by molecular type, some
authors have suggested that antimicrobial susceptibility may
continue to be a distinguishing characteristic of community-
acquired MRSA [10–12].
To better understand the current epidemiology of CA-MRSA in
a population that includes rural communities, we conducted
a study of MRSA nasal colonization of patients at the time of
admission to Penn State Hershey Medical Center (PSHMC),
a 500-bed tertiary care center in south-central Pennsylvania.
Methods
Ethics Statement
The Johns Hopkins Bloomberg School of Public Health and
Penn State Hershey Medical Center Institutional Review Boards
reviewed and approved this study. Patients gave written informed
consent for participation in the study.
Hospital Surveillance
As part of an ongoing hospital surveillance program, nasal
swabs were performed on all patients admitted to PSHMC, except
those in the obstetrical wing, who did not have a known prior
diagnosis of MRSA.
Research Design
As part of a study designed to evaluate risk factors for MRSA
nasal carriage related to household and rural exposures, we
approached patients admitted between August 2009 and March
2010. Patients who were over 18 years of age and were screened
for MRSA on admission were eligible to participate in our study.
After obtaining informed consent, we interviewed both positive
and negative MRSA case-patients. This manuscript is limited to
the analysis of the risk factors reported by patients identified with
a positive nasal swab and isolates from those case-patients that
were subsequently confirmed positive by culture and molecular
methods, strain-typed by MLST, and tested for antimicrobial
susceptibility.
Survey
Patients were interviewed for self-reported risk factors that
included location of residence, demographic information, and
hospitalization within the past month, six months, or year prior to
admission. Epidemiologic categorization of MRSA isolates from
case-patients as ‘‘healthcare-associated’’ was based on answers of
‘‘yes’’ to ‘‘Have you been hospitalized at any point in the past a)
year, b) six months, or c) one month?’’ and we defined patient
hospitalization exposure as an admission to a healthcare setting
lasting eight hours or longer. Patient records were reviewed for
long-term healthcare residence immediately prior to hospital
admission, and patients with such residence also were classified as
HA-MRSA case-patients. History of antimicrobial use, which has
been included in some alternative definitions of healthcare-
associated MRSA, was left out of our definition to allow it to be
examined separately.
Sample Collection
Swabs of the anterior nares of patients were collected within 48
hours of admission. These swabs were processed using the BD
GeneOhm
TM MRSA Assay (Becton Dickinson Diagnostics, San
Diego, CA). This method allows for direct detection of MRSA
from the nasal specimen and has a manufacturer-reported
sensitivity of 93% and a specificity of 96%. This PCR-based assay
detects unique gene sequences for identification of both S. aureus
(orfX) and of methicillin resistance (SCCmec) [20,21]. Positive
nasal swabs were inoculated into trypticase soy broth (TSB) +20%
glycerol and archived at 280uC.
All available PCR-positive nasal swabs from patients enrolled in
the study were cultured for MRSA. A 10 ml loop of broth from
each archived nasal swab was plated onto commercial MRSA
Select
TM agar plates (Bio-Rad Laboratories, Hercules, CA) and
incubated for up to 48 hours at 35uC [22]. Archived swabs that did
not demonstrate positive growth on a first culture attempt were
inoculated into enrichment broth (Mueller-Hinton broth +6.5%
NaCl) and incubated for 24 hours at 35uC. From the overnight
enrichment, a second attempt was made to isolate positive cultures
on MRSA Select
TM agar.
Molecular Methods
DNA was extracted from isolates using ZR-96 DNA extraction
kits (Zymo Research, Orange, CA). Isolates were tested using
a real-time PCR assay to confirm MRSA genotype by detection of
mecA and femA genes (Pathogene, LLC). Isolates positive for femA
but negative for mecA (MSSA) on real-time PCR were re-tested
using a new universal mecA primer as previously described [23].
Additionally, isolates were tested for the Panton Valentine
leukocidin toxin using a real-time PCR assay for the lukPVSF
region as described previously [24].
Confirmed MRSA isolates were typed by multi-locus sequence
typing (MLST) as described previously [25]. Sequences from seven
housekeeping genes were compared to an online database (www.
mlst.net) to identify a match for each allele at that locus, allowing
strains to be assigned a numerical strain type (ST) based on the
allelic profile. Using eBURST software (eburst.mlst.net), related
clusters of MRSA sequence types were grouped into Clonal
Complexes (CC), which consist of a main or progenitor ST and
other STs that differ by one or two alleles [25,26].
Antimicrobial Susceptibility Testing
Confirmed MRSA isolates were tested subsequently for
antimicrobial susceptibility using disc diffusion methods [27,28],
including erythromycin-induced resistance to clindamycin (D-test),
following CLSI guidelines [29]. Antibiogram classifications were
made on the basis of susceptibility to seven antimicrobials:
tetracycline (Te), gentamicin (GM), amikacin (AN), trimetho-
prim/sulfamethoxazole (SXT), clindamycin (CC), ciprofloxacin
(CIP), and erythromycin (E). Multi-drug resistance (MDR) was
defined as beta-lactam resistance by mecA gene presence plus
nonsusceptibility (inducible, intermediate or high-level resistance)
to three additional classes of antimicrobials by disc diffusion
methods, based on a definition reported by SENTRY [30].
Statistical Analysis
We estimated associations between hospital risk factor, pheno-
typic, and genotypic classification methods using prevalence ratios.
We calculated estimates of association (prevalence ratios) using
Poisson models with robust estimation of standard errors as
described previously [31,32] using Stata 11 (College Station, TX).
We evaluated the effect of changing the temporal cutoff for our
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for our results based on hospital risk factor-based classification.
Reference groups were assigned to the largest strata.
Results
Case-patient Selection
We approached 657 patients at Penn State Hershey Medical
Center (PSHMC) between August 2009 and March 2010. Of
these, 408 (62%) consented, including 151 MRSA screen- positive
case-patients and 257 screen-negative case-patients. Of the 151
case-patients, 94 had isolates confirmed as MRSA available for
MLST analysis and antimicrobial susceptibility testing, and
therefore were included in this analysis.
Epidemiologic comparison of the 57 case-patients for whom
MRSA isolates were not available demonstrated that these patients
did not differ significantly in demographic characteristics, rates of
prior hospitalization, or self-reported antimicrobial use as com-
pared to the 94 patients for whom isolates were available for
further genotypic and phenotypic analysis.
MLST Genotypes
The most common sequence type was ST5 (34 isolates). Fifty-
one isolates (55%) were associated with clonal complex 5 (CC5),
which includes ST5, ST225, and the third most common type,
ST105 (11 isolates). Twenty-seven isolates (29%) were associated
with clonal complex 8 (CC8), which includes ST72 (1 isolate) and
the second most common type, ST8 (26 isolates). Additional
sequence types included: ST1 (n=5), ST15 (n=2), ST30 (n=1),
ST59 (n=1), ST81 (n=1), ST221 (n=1), ST474 (n=1) & ST496
(n=1). A ST could not be assigned to three isolates; one of these
isolates was determined to be a novel sequence, one was non-
typable, and one, originally negative for mecA on qPCR, never was
tested by MLST but later was found to be positive for mecA using
a universal mecA primer according to Holden et al. [23]. CC8 and
CC5 strains were isolated from case-patients with similar age and
gender characteristics. Case patients with CC8 isolates were less
likely than case patients with CC5 isolates to report recent
antimicrobial use (PR 0.97 for one to six months prior use, and PR
0.53 for use within the past month), but these estimates of
association were not statistically significant (p=0.93 and p=0.10,
respectively).
Antimicrobial Susceptibility Phenotypes & Pvl Gene
Presence
We identified 30 antimicrobial susceptibility profiles among the
94 isolates representing 15 different ST types (Figure 1). Only
seven isolates were pan-susceptible to the tested antimicrobials,
and one was resistant to all antimicrobials tested. Among case-
patients without any history of hospitalization, three (9%) were
nonsusceptible to tetracycline, two (6%) to trimethoprim-sulfa-
methoxazole and 18 (55%) to clindamycin. Of 94 MRSA isolates
tested, 66 (70%) overall were nonsusceptible to $4 classes of
antimicrobials (MDR). All pvl-positive isolates were ST8 (CC8)
strains. Of the 19 pvl-positive isolates, 4 (21%) were MDR.
Classification as HA- or CA-MRSA by Hospitalization Risk
Factor
Among patients with CC5 isolates, 25% reported no history of
hospitalization in the past year and 43% reported no history of
hospitalization within six months of admission (Table 1). Among
patients with CC8 isolates, 59% reported being hospitalized in the
past year, and 33% reported being hospitalized within six months.
We examined the effects of varying cutoff criteria for
hospitalization risk factor-based classification by assigning cases
as epidemiologically HA-MRSA versus CA-MRSA based on self-
reported patient histories of hospitalization within one year, six
months, or one month of admission (Table 1). If cases were
classified as epidemiologically HA-MRSA using the cutoff of
hospitalization within the past six months, then there was an
association with both CC5 genotype (PR 1.71, p=0.08) and MDR
(nonsusceptibility to $4 antimicrobials) profile (PR 2.34, p=0.01).
(Table 1 provides this comparison using the larger CC5 group as
the reference instead.) Estimates of association were similar but
non-significant when cutoffs were used of hospitalization within
the past month or within the past year. However, using genotype
as a gold standard, a negative history of hospitalization within six
months provided a predictive value of only 45% for CA-MRSA
and a positive history of hospitalization provided a predictive value
of 76% for HA-MRSA in our study population. Changing the
history of hospitalization cutoff provided similar predictive values
for one-month and one-year time frames.
We examined whether presence of the Panton-Valentine
leukocidin gene (pvl) was associated with epidemiologic classifica-
tion. MRSA case-patients without a history of hospitalization
within one year, six months, or one month were 1.67, 1.56, or 1.24
times more likely than HA-MRSA case patients to be colonized
with pvl-positive isolates, respectively; however, only the estimate
of association for the six-month cutoff was statistically significant
(p=0.07, p=0.02, or p=0.09, respectively).
Sensitivity Analysis with Age Restriction
Because of our interest in community-associated MRSA, we
performed a sensitivity analysis to examine estimates of association
for a subset of case-patients by restricting models to participants
who were under the age of 65. This removed the older population
more likely to have recent indirect healthcare contact, e.g. home
care or spousal residence in a nursing home. MRSA case-patients
under the age of 65 without long-term care home residence or
history of hospitalization within one year, six months, or one
month were 2.43, 1.53, or 1.18 times more likely to be CC8
compared to CC5 genotypes, respectively (n=45); however, only
the estimate of association for the one-year cutoff was statistically
significant (p=0.05, p=0.11, or p=0.35, respectively). These CA-
MRSA cases also were 2.24, 1.62 or 1.21 times more likely to be
non-MDR, respectively (n=53), but only the estimates of
association for the one-year and six-month cutoffs were statistically
significant (p=0.02, p=0.03, or p=0.23, respectively).
Antimicrobial Susceptibility Profiles by MLST Type
Table 2 presents prevalence of susceptibility by antimicrobial
according to ST type and clonal complex. Compared to CC5
isolates, CC8 isolates had a 3.78 [95% CI: 2.38–6.00] fold higher
prevalence of ciprofloxacin susceptibility (p,0.001); a 9.72 [95%
CI: 3.71–25.46] fold higher prevalence of clindamycin suscepti-
bility (p,0.001); and a 3.22 [95% CI: 1.23–8.43] fold higher
prevalence of amikacin susceptibility (p=0.02). CC8 isolates had
a 6.05 [95% CI: 3.10–11.78] fold higher prevalence of suscepti-
bility to four or more classes of antimicrobials, i.e., non-MDR
(p,0.001).
Geographic Classification
Eight of 94 case-patients (9%) reported residence in the city of
Harrisburg, one reported out-of-state residence, and two did not
report location of residence. The remaining 83 case-patients (88%)
reported non-urban residence in Pennsylvania, with 25 (27%)
reporting residence in rural counties (i.e., population density less
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palegislature.us/rural_urban.html). We did not find significant
associations between 2010 Census county population density or
rural county residence and prevalence of strains by genotype,
multidrug resistance, or hospital risk factor classification (results
not shown).
Discussion
In this study, we found that classification by history of
hospitalization did not correlate well with the genotypes of MRSA
that historically had emerged in association with hospitals (e.g.,
CC5 complex, associated with PFGE type USA100), and that
absence of hospitalization history also did not correlate with those
genotypes that historically had emerged in patients without the
association with healthcare (e.g., CC8 complex, associated with
PFGE type USA300). We did not test for SCCmec types, which
may vary within MLST strain type; this is a limitation of our study.
Our data indicate a shift in the epidemiology of CC8 strains such
that a majority of these strains were isolated from patients who
report a history of hospitalization, although a statistical trend
remained for community association with CC8 strains and strains
carrying the pvl gene. Conversely, a quarter of CC5 strains in our
cohort came from patients without recent hospitalization. This
possible shift could be due to circulation of strains of community
origin in the hospital, and, to a lesser extent, dissemination of
strains of hospital origin into the community.
These findings are consistent with recent reports of MRSA
epidemiology in the United States [6,15,18,33,34] and interna-
tionally [14,16,17,19]. Among children admitted in 2007 to the
PICU at Johns Hopkins Hospital (which, like our study site, is
a mid-Atlantic tertiary care center), CA-MRSA (USA300) isolates
were found on admission (nasal colonization) and also isolated
from hospital-associated MRSA infections [15]. Similar trends for
USA300 strains have been seen among healthcare-associated
bloodstream infections in the U.S. [11,34], healthcare-associated
infections internationally [35], and in a national Active Bacterial
Core surveillance system [36].
The definition we used for HA- versus CA-MRSA is similar to
common definitions used in the literature. Naimi et al. have defined
HA-MRSA based on criteria of prior MRSA diagnosis, MRSA
cultured on a test performed more than 48 hours after hospital
admission (both not applicable in our study by design), history of
hospitalization, surgery, dialysis or residence in a long-term care
facility within a year before the culture date, or a permanent
device such as an indwelling catheter present at the time of culture
[37]. Analysis of our epidemiologically-based classification of HA-
MRSA versus CA-MRSA cases suggests that a cutoff of
hospitalization within six months rather than one year may be
more consistent with isolate genotypic and antimicrobial pheno-
typic characteristics; the association, however, was not strong. This
finding may reflect nasal persistence of strains or host character-
istics within our cohort. For example, a European study found
that, among patients colonized with MRSA, the median duration
of colonization was seven months [38].
Figure 1. Heat map of antimicrobial susceptibility patterns for 94 methicillin-resistant Staphylococcus aureus (MRSA) strains from
Penn State Hershey Medical Center, August 2009 to March 2010.
doi:10.1371/journal.pone.0038354.g001
Table 1. Impact of changing the cutoff point of history of hospitalization from within prior year to within prior six months or one
month on classification as HA-MRSA vs. CA-MRSA according to strain (ST) and clonal complex (CC) assignment from multi-locus
sequence typing (MLST) and according to multi-drug resistance phenotype.
Hospitalization
In the past year
(HA)
Not in the past
year (CA)
In the past
six months (HA)
Not in the past
six months (CA)
In the past
month (HA)
Not in the past
month (CA)
Genotype (n=78)
All CC8 (n=27) 16 (59%) 11 (41%) 9 (33%) 18 (67%) 5 (19%) 22 (81%)
ST8 (n=26) 16 (62%) 10 (38%) 9 (35%) 17 (65%) 5 (19%) 21 (81%)
All CC5 (n=51) (reference) 38 (75%) 13 (25%) 29 (57%) 22 (43%) 19 (37%) 32 (63%)
ST5 (n=34) 25 (74%) 9 (26%) 18 (53%) 16 (47%) 12 (35%) 22 (65%)
ST105 (n=11) 9 (82%) 2 (18%) 8 (73%) 3 (27%) 5 (45%) 6 (55%)
PR
b for CC8 (CA vs HA) 1.59 ref 1.55 ref 1.30 ref
[95% CI] [0.83–3.09] ref [1.02–2.34] ref [0.98–1.72] ref
p-value p=0.16 ref p=0.04 ref p=0.07 ref
Phenotype (n=94)
Not MDR (n=28) 15 (54%) 13 (46%) 7 (25%) 21 (75%) 5 (18%) 23 (82%)
MDR (n=66) (reference) 46 (70%) 20 (30%) 38 (58%) 28 (42%) 22 (34%) 43 (66%)
PR for susceptibility (CA vs HA) 1.53 ref 1.76 ref 1.24 ref
[95% CI] [0.89–2.64] ref [1.24–2.52] ref [0.97–1.59] ref
p-value p=0.12 ref p=0.002 ref p=0.09 ref
Values are n (%). Multi-drug resistance is defined as non-susceptibility beta-lactam drugs plus three or more classes of antimicrobials. Beta-lactam resistance is
determined by the presence of the mecA gene.
aMissing information for hospitalization within one month for 1 individual. This individual had a non-CC8, non-CC5 isolate that was multi-drug resistant and is excluded
from analysis by isolate phenotype.
bPR: Prevalence Ratio.
doi:10.1371/journal.pone.0038354.t001
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cin, and amikacin significantly differentiated strains by genotype,
with CC5 isolates showing generally more frequent resistance and
CC8 isolates showing more frequent susceptibility to these three
antimicrobials. High rates of ciprofloxacin resistance, even among
isolates from CA-MRSA case-patients, may limit future discrim-
inatory performance for this antimicrobial in this and similar
patient populations. Results are consistent with clindamycin
susceptibility reported in U.S. MRSA isolates with community
genotypes (USA 300/CC8) [39] or community SCCmec types
(SCCmec IV) [40].
Multidrug resistance (nonsusceptibility to $4 classes of anti-
microbials) was highly prevalent in MRSA isolates from this
PSHMC cohort. The overall rate of MDR was 70%, and even
among historically-susceptible CC8 isolates, the rate of MDR was
30%. This generally is higher than earlier reports in the United
States [10,41,42]. Within MLST type, strains were not uniform by
antimicrobial susceptibility phenotype (antibiogram). While
MLST designation relates to evolutionary MRSA lineage [43],
antibiogram differences within strain likely reflect more recent
genetic divergence characterized by acquisition of resistance.
This descriptive, observational study has several limitations.
First, our results are restricted to comparisons within culturable
isolates, and by necessity excludes 57 (38% of 151) MRSA case-
patients whose nasal swabs were not available for culture as well as
those whose presumptive MRSA-positive swabs did not grow on
selective media. The latter may represent a source of selection bias
for hardier strains or represent a bias favoring case patients with
higher concentrations of nasal bacterial colonization more
amenable to culture. Second, because we studied a single hospital
inpatient cohort, results may not be generalizable to other adult
populations. Third, we did not collect information by interview on
all sources of potential exposure to healthcare settings, including
dialysis, which could result in misclassification of cases as
community- rather than healthcare-associated. However, an
analysis restricted to participants aged 18–65, excluding the
elderly case-patients who may have distinct risk factors such as
unreported non-hospital healthcare facility or home care nursing
contact, did not strongly influence the estimates of association.
Finally, because risk factors were based on self-report, recall bias
may result in misclassification, e.g., by the hospitalization history
classification method.
This study is strengthened by use of a hospital-wide surveillance
program rather than selective risk-based testing for case-patient
ascertainment. Because of the nature of the health care facility, it
contributes to the literature on MRSA epidemiology by including
participants from rural communities.
These results indicate discordance between patient risk factor
epidemiology in relation to the MRSA isolates’ genotypic and
antimicrobial resistance characteristics. The ever-increasing shift
of healthcare from acute hospitals to non-acute and home settings
may in part explain the findings. As CA-MRSA strains enter
healthcare settings, and HA-MRSA strains disseminate to the
community, isolate genotype and antimicrobial susceptibility
phenotype provide different pieces of information to track
movement of strains and inform community clinical practice and
hospital infection control efforts.
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Table 2. Prevalence of susceptibility to seven antimicrobials, by strain (ST) and clonal complex (CC), among 94 isolates.
ST 5 (CC5)
(n=34)
ST 105 (CC5)
(n=11) All CC5 (n=51)
ST 8 (CC8)
(n=26) All CC8 (n=27) p-value
All isolates
(n=94)
Erythromycin (ERY) 1 (3%) 0 (0%) 1 (2%) 5 (19%) 5 (19%) 0.001 10 (11%)
Ciprofloxacin (CIP) 1 (3%) 0 (0%) 1 (2%) 10 (38%) 11 (41%) ,0.001 18 (19%)
Clindamycin (CLI) 5 (15%) 0 (0%) 6 (12%) 23 (88%) 23 (85%) ,0.001 36 (38%)
Amikacin (AMK) 13 (38%) 9 (82%) 27 (53%) 22 (85%) 23 (85%) 0.02 62 (66%)
Trimethoprim/
sulfamethoxazole (SXT)
31 (91%) 9 (82%) 45 (88%) 23 (88%) 24 (89%) 0.93 81 (86%)
Gentamicin (GEN) 31 (91%) 9 (82%) 46 (90%) 25 (96%) 26 (96%) 0.41 85 (90%)
Tetracycline (TET) 31 (91%) 11 (100%) 48 (94%) 25 (96%) 25 (93%) 0.95 86 (91%)
Values are n (%) for susceptibility (excluding isolates with inducible, intermediate, or high-level resistance).
P-values are reported for comparisons between CC8 and CC5 (reference).
CC5 includes ST5 (n=34), ST105 (n=11) and ST225 (n=6). CC8 includes ST8 (n=26) and ST72 (n=1).
doi:10.1371/journal.pone.0038354.t002
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